Adipose tissue stem cells meet preadipocyte commitment: going back to the future

William P. Cawthorn,1,* Erica L. Scheller,1,* and Ormond A. MacDougald2,*

Department of Molecular and Integrative Physiology,* University of Michigan, Ann Arbor, MI 48109

Abstract

White adipose tissue (WAT) is perhaps the most plastic organ in the body, capable of regeneration following surgical removal and massive expansion or contraction in response to altered energy balance. Research conducted for over 70 years has investigated adipose tissue plasticity on a cellular level, spurred on by the increasing burden that obesity and associated diseases are placing on public health globally. This work has identified committed preadipocytes in the stromal vascular fraction of adipose tissue and led to our current understanding that adipogenesis is important not only for WAT expansion, but also for maintenance of adipocyte numbers under normal metabolic states. At the turn of the millennium, studies investigating preadipocyte differentiation collided with developments in stem cell research, leading to the discovery of multipotent stem cells within WAT. Such adipose tissue-derived stem cells (ASCs) are capable of differentiating into numerous cell types of both mesodermal and nonmesodermal origin, leading to their extensive investigation from a therapeutic and tissue engineering perspective. However, the insights gained through studying ASCs have also contributed to more-recent progress in attempts to better characterize committed preadipocytes in adipose tissue. Thus, ASC research has gone back to its roots, thereby expanding our knowledge of preadipocyte commitment and adipose tissue biology.—Cawthorn, W. P., E. L. Scheller, and O. A. MacDougald. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J. Lipid Res. 2012. 53: 227–246.

Supplementary key words adipocytes • bone marrow • signal transduction • preadipocytes

FROM HIPPOCRATES TO ADIPOSE TISSUE-DERIVED STEM CELLS: A BRIEF HISTORY OF PREADIPOCYTES AND ADIPOSE TISSUE STEM CELLS

White adipose tissue (WAT) is generally viewed negatively, cast under the shadow of obesity and its association with ill health. Such stigmatization distracts from a fascinating aspect of WAT biology: its enormous plasticity as an organ. Indeed, WAT is capable of massive expansion and contraction in response to chronic alterations in energy balance, accounting for as little as 5% body mass in extremely lean athletes (1) or as much as 60% body mass in morbidly obese individuals (2). Moreover, in rodents, rabbits, and humans, WAT can regenerate following lipectomy (3–6). This striking degree of plasticity is unique among organs in adults. On a cellular level, WAT expansion is driven by both hypertrophy and hyperplasia of adipocytes (7–13). Even in nonexpanding WAT, adipocytes renew frequently to compensate for adipocyte death, with approximately 10% of adipocytes renewed annually (14, 15). These data, which indicate that committed adipocyte progenitors (preadipocytes) exist within WAT, are the product of decades of research motivated largely by our desire to understand adipose tissue in the context of obesity and related diseases.

Preadipocytes exist in adipose tissue

Though the notion of obesity as a disease has existed since at least the time of Hippocrates (16), investigation into the origins of the adipocyte and the individual contributions of adipocyte hypertrophy and hyperplasia to adipose bulk began in earnest only after the appearance of the stem cell concept, as related to blood cells, in the early 1900s (17). In the 1940s, histologic observations of the appearance of adipocytes in chambers implanted in the ears of live rabbits suggested that de novo fat formation was...
possible (18). Closer inspection revealed that new adipocytes formed only along the vasculature (18) (Fig. 1), extending earlier reports linking vascularization and fat formation (19) and foreshadowing our current realization that some preadipocytes reside in a perivascular niche (20–25). Subsequent studies confirmed the existence of a mitotically active cell population in WAT (7), and that WAT expansion is associated with increases in total DNA content and adipocyte number (26). Following the development of methods for separating WAT into adipocyte and stromal vascular fractions (SVFs) (27), the source of these new adipocytes was determined by Hollenberg and Vost (28); using tritiated thymidine to monitor DNA synthesis in WAT, they detected temporal progression of radioactivity from the SVF to mature adipocytes, thereby inferring the presence of an adipocyte precursor cell in the SVF (28). Shortly thereafter, studies reported growth of fibroblast-like cells from the SVF that are capable of adipogenesis (29–31). This led to the designation of these stromal vascular cells (SVCs) as “primary” preadipocytes, setting the stage for extensive characterization of the mechanisms regulating adipogenesis and WAT expansion.

**Expanding knowledge of adipogenesis**

The ability to isolate SVCs from WAT of distinct depots and under diverse conditions, such as with aging or obesity, forms the basis for our understanding of how these factors impact adipogenesis. For example, in humans, SVCs from visceral WAT are less proliferative and adipogenic and more susceptible to apoptosis than are SVCs from subcutaneous depots (32–34), whereas in rodents, SVCs of epididymal WAT show the poorest potential for adipogenesis or proliferation (35–40). Similar differences occur with aging, which is associated with decreased proliferation (35, 37, 38) and adipogenesis (41–43) of SVCs; the latter perhaps accounts for observed increases in preadipocyte number with age (44). In contrast, SVC proliferation is enhanced in massively obese humans (45), although obesity may only be associated with impaired SVC adipogenesis in older individuals (32, 46). Ultimately, such studies of SVC adipogenesis have highlighted how preadipocyte function might impact whole WAT biology in normal and disease states. However, SVCs are a heterogeneous cell population that, in addition to preadipocytes, contains fibroblasts, leukocytes, epithelial cells, endothelial cells, and other cells comprising the vasculature and nerve tissue (40, 47–49) (Fig. 2). SVCs also have practical limitations, such as inconsistent adipogenic differentiation and senescence during prolonged culture. To overcome these drawbacks, several clonal preadipocyte lines have been established, most notably the murine 3T3-L1 preadipocyte line (50–52). The use of these cell lines has facilitated extensive investigation of adipogenesis on a molecular level, leading to detailed characterization of extracellular modulators, intracellular signaling pathways, and, notably, transcriptional mechanisms that impact and underlie adipocyte differentiation. These developments have been reviewed extensively elsewhere (53–57) and continue to be refined and extended to this day, especially through global profiling of epigenetic modifications and transcription factor binding sites using DNase hypersensitivity, ChIP-chip or ChIP-seq analysis (58–61). Thus, the study of both SVCs and preadipocyte lines has made an enormous contribution to our current understanding of adipogenesis and WAT biology.

**Adipose tissue enters the world of multipotent stem cells**

This progress in our knowledge of preadipocyte differentiation paralleled that made in the field of stem cell biology. Although the term “stem cell” was first used in 1868, it was not applied in its modern context until the early 1900s, when it became used to describe the putative common progenitor for the hematopoietic system (17). Definitive evidence for existence of a common hematopoietic stem cell (HSC) emerged in the 1960s (62–64), followed by extensive HSC characterization based on cell surface markers (65). Importantly, HSCs are capable of both self-renewal and multilineage differentiation in vivo (66), two properties that are considered definitive of a true stem cell population (67). In addition to HSCs, bone marrow (BM) stroma also contains nonhematopoietic progenitor cells, the existence of which was first inferred through observations of donor cell-derived osteogenesis following BM transplants (68). These stromal cells can be separated from HSCs based on the inability of the latter to adhere in culture (as reviewed in Ref. 69); thereby isolated, these stromal cells display at least some capacity for self-renewal (70–72) and differentiation into mesenchymal cell types.

---

**Fig. 1.** New adipocyte formation along the vasculature. Transparent chambers were implanted into the ears of live rabbits, allowing visualization of de novo adipocyte formation during tissue revascularization; adipocytes appear as dark outgrowths around the vasculature. The authors of this study (18) observed that “Frequently the fat cells appeared first in close proximity to a blood vessel ... the first fat cells in the right ear (A) appeared beside a vein, later spreading to the tissue between the blood vessels ... Frequently the new fat was first seen in one or two localized regions of the table area and subsequently it gradually spread out from those foci into adjoining regions (B).” This material is reproduced from (18) with permission from John Wiley and Sons, Inc.
Fig. 2. Relationships between SVCs, ASCs, committed preadipocytes, and mature adipocytes. Typical surface markers and other genes expressed or absent in each cell type are shown. More-extensive lists of surface markers and cell fates are provided, with citations, in Tables 1 (or see supplementary Table 1) and 2, respectively. Comparisons of surface markers or other genes differentially expressed between the different cell types reveal potential mechanisms of preadipocyte commitment. Factors that positively regulate preadipocyte commitment are shown in red, and negative regulators are shown in green; effects of PDGF on preadipocyte commitment remain uncertain. Arrows shown as dotted lines designate pathways that are not yet firmly established. For example, whether committed preadipocytes continuously derive from ASCs or merely replenish through autologous self-renewal remains incompletely understood. Equally, whether ASCs or committed preadipocytes can revert to pericytes or ASCs, respectively, requires further investigation. Although mature adipocytes can give rise to other cell types in experimental conditions, the relevance of such trans-differentiation to physiological contexts is not clear. Finally, formation of adipocytes from BM HSCs, fibrocytes, or the neural crest has been reported, so it is possible that ASCs derive from some of these cell types; however, these findings remain controversial.
such as osteoblasts, chondrocytes, adipocytes, and myoblasts, both in vitro and in vivo (69, 72–74). Based on these properties, such cells have been designated mesenchymal stem cells (MSCs). Related approaches have resulted in the identification of neural crest stem cells (75), as well as MSCs in numerous other tissues (76).

At the turn of the millennium, these parallel developments in our understanding of preadipocyte differentiation and stem cell biology collided, with the discovery of multipotent stem cells in WAT (77–79). The past decade has since witnessed an explosion in research focusing on such adipose tissue-derived stem cells (herein referred to as ASCs, but given various names in other studies3), largely fueled by interest in their potential for tissue engineering and regenerative medicine (80). Consequently, there is now a wealth of information regarding ASC multipotency, both in vitro and in vivo (Table 2). However, before discussing this, it is necessary to address a fundamental and still-unresolved question: what exactly is an ASC?

DEFINING THE ASC

The rapid expansion in ASC research has often generated conflicting findings, which is partly attributable to inconsistency and uncertainty in defining the ASC itself. Whereas some studies describe whole, unsorted SVC populations as “ASCs” (100–102), others define ASCs as a functionally distinct SVC subpopulation (49, 103–105); in yet other cases, it is not clear whether the ASCs investigated are whole SVCs or a subpopulation of these. Moreover, SVCs have been analyzed as freshly isolated cells (106, 107) or after different durations in culture (103, 108), with some studies drawing comparisons between these conditions (22, 109). Even naming of the ASC has varied hugely. These inconsistencies complicate our ability to draw meaningful conclusions across multiple studies, underscoring the need to better define exactly what the ASC is. Many insights are provided through extensive functional analyses of ASC multipotency, as discussed elsewhere. Additionally, ASCs have been characterized through global analyses of gene expression (108, 110, 111) and protein secretion (112), and by more-focused approaches, such as assessment of epigenetics (113), circadian genes (114), or electrophysiological properties (115). However, by far the most widespread analyses are of cell surface markers.

Beauty is only skin deep: cell surface markers in ASC characterization

Extensive study of HSCs has established the utility of using cell surface markers to characterize genuine stem cells within a heterogenous cell population (65, 66). This is also true for BM MSCs, which are defined by the International Society for Cellular Therapy as being CD73+, CD90+, CD105+, CD45−, CD34−, or CD11b−, CD79−, or CD19−, and devoid of human leukocyte antigen-DR (Table 1, supplementary Fig. 1) (116). Similarly, numerous studies have characterized whole SVCs or ASCs based on surface marker expression (Table 1 and supplementary Fig. 1), and several researchers have suggested definitive marker profiles for ASCs. For example, Yoshimura et al. designate ASCs as a CD34+/CD31−/CD45−/CD90+/CD105−/CD146− subpopulation of SVCs (49); Lin et al. suggest that ASCs are CD34+/CD31−/CD104b− and negative for α-smooth muscle actin (α-SMA) (117); and Quirici et al. used positive selection for CD34 and CD271 (L-NGFR) to identify ASCs based on their capacity for proliferation and multilineage differentiation (118). However, the heterogeneity and evolution of surface phenotypes in long-term culture bring into question the ability to reliably identify a “phenotypic fingerprint” of a stromal stem cell based on surface markers alone; like beauty, many of the most attractive surface markers fade with time as cells are maintained and passaged in vitro (21, 49, 88, 103, 119, 120). Species-specific differences in surface marker expression could also account for discrepancies between studies based on murine or human cells. Finally, most of the markers are not directly related to the stem cell itself and are often expressed on nonprogenitor lineages. Perhaps because of these drawbacks, agreement for a definitive ASC marker profile remains to be established. Therefore, in Table 1, we present a concise list of surface markers differentially expressed between these cell types in an attempt to find some consensus on marker profiles typical of ASCs; a more comprehensive overview is shown in the supplement (see supplementary Table 1). Such an overview allows direct comparison of marker expression between BM MSCs, whole WAT SVCs, and purified ASCs, which we feel can provide further insights into ASC biology. For example, numerous markers are expressed or absent in both BM MSCs and ASCs, suggesting much similarity between these cell types. In contrast, several markers distinguish BM MSCs from ASCs, including CD34, CD104, CD106, and possibly CD49d (Table 1). Equally, differences between ASCs and whole SVCs potentially exist in expression of CD11a, CD14, CD31, CD34, CD45, CD117, CD146, and von Willebrand factor (Table 1 and supplementary Table 1), which might facilitate isolation of ASCs from whole SVC populations. Indeed, the use of surface markers has been pivotal to recent progress in localizing ASCs within WAT.

---

3The cells described herein as ASCs have had many other aliases. In 2001, Zuk et al. published the first report of multipotent cells in adipose tissue, naming these processed liposapirrate cells (PLAs) based on their method of isolation (78); hence, numerous later studies also refer to these cells as PLAs (81–85). At around the same time, Gimble and colleagues identified adipose tissue-derived stromal cells that were categorized as PLAs (81–85). At around the same time, Gimble and colleagues identified adipose tissue-derived stromal cells that were categorized as PLAs (81–85). At around the same time, Gimble and colleagues identified adipose tissue-derived stromal cells that were categorized as PLAs (81–85).
Adipose tissue stem cells meet preadipocyte commitment

Other studies (22, 49, 123, 124). Pericytes thereby isolated using fluorescence-activated cell sorting (FACS) were found to be multipotent, even after long-term passaging in culture, and to express MSC markers such as CD44, CD73, CD90, and CD105 (Table 1) (121). Of two initial studies focusing on the perivascular nature of ASCs specifically, one reported findings very similar to those of Crisan et al. (121) whereas another found that CD34+/CD31– ASCs are also perivascular (22, 23). Further evidence comes from more-recent work based on \( ^{14} \text{H}9251 \)-SMA expression. In transgenic mice that express green fluorescent protein (GFP) from the \( ^{14} \text{H}9251 \)-SMA promoter, \( ^{14} \text{H}9251 \)-SMA-expressing cells in WAT are exclusively perivascular, as assessed by tissue localization and coexpression of platelet-derived growth factor.

Increasing evidence suggests that MSCs from multiple human tissues, including WAT, are perivascular cells (pericytes) (21, 22, 121). Defined anatomically in vivo based on their location surrounding the endothelia (122), pericytes can be distinguished from endothelial and smooth muscle cells by their extensive cytoplasmic branching, abundant rough endoplasmic reticulum, moderate amounts of lysosome-like bodies, and abundance of micropinocytotic vesicles (122). Functionally, pericytes can modulate both endothelial cell proliferation and vessel contractility (121). Using immunostaining, Crisan et al. identified pericytes in multiple organs as CD146+, NG2+ CD140b+, \(^{14} \text{H}9251 \)-SMA+, CD144–, vWF–, CD34–, and CD31– (121), consistent with other studies (22, 49, 123, 124). Pericytes thereby isolated using fluorescence-activated cell sorting (FACS) were found to be multipotent, even after long-term passaging in culture, and to express MSC markers such as CD44, CD73, CD90, and CD105 (Table 1) (121).

**TABLE 1.** Surface marker expression in BM MSCs, SVCs, ASCs, committed preadipocytes (preads), and mature adipocytes (Ads)

| Marker | BM MSCs | MSCs (ISCT criteria) | SVCs (unsorted) | ASCs | Committed preads | Ads | Marker expression pattern |
|--------|---------|----------------------|-----------------|------|-----------------|-----|------------------------|
| CD166  | ALCAM   | (72, 126)            | (105)           | (21, 86, 103, 132, 174, 245) | (28, 189) | Distinct between ASCs and SVCs |
| CD45   | FPRC    | (72, 81, 111, 159, 172, 232) | (115) | (21, 43, 81, 86, 98, 189, 103, 145, 152, 170, 245) | (28, 189) |
| vWF    | von Willebrand Factor | (72) | (105) | (47, 103, 121) | |
| Lin    | Lineage antigens* | | (158, 189) | (98) | | (189) |
| CD31   | PECAM-1 | (72, 81, 111, 119, 172, 232) | (116) | (22, 47, 49, 105, 109, 127, 245) | (105) | Distinct between ASCs and SVCs |
| CD34   | CD34; stem cell marker; CD62L receptor | (72, 81, 111, 159, 172, 232) | (116) | (22, 47, 49, 105, 109, 127, 245) | (105) | |
| CD117  | c-kit; SCFR | (172, 352) | (165) | (165) | | (189) |
| CD105  | Endoglin; SH2 | (72, 81, 92, 172, 252) | (165) | (165) | | (189) |
| CD140a | PDGFR-α | (165) | (165) | (165) | | (189) |
| CD24   | BA-1 (binds to P-selectin) | (165) | (165) | (165) | | (189) |
| CD29   | β1-integrin | (72, 81, 92, 172, 252) | (165) | (165) | | (189) |
| CD140b | PDGFR-β | (165) | (165) | (165) | | (189) |
| Sca-1  | stem cell antigen-1; Ly-6A-2 | (165) | (165) | (165) | | (189) |
| CD62L  | L-selectin; LECAM-1 | (165) | (165) | (165) | | (189) |
| CD104  | β4-integrin | (165) | (165) | (165) | | (189) |
| CD106  | VCAM-1 | (165) | (165) | (165) | | (189) |
| CD49d  | αv-integrin; VLA-4 | (165) | (165) | (165) | | (189) |
| Stro-1 | Stromal cell antigen-1 | (165) | (165) | (165) | | (189) |

* Lin antigens consist of: CD2, CD3, CD4, CD5, CD8, NK1.1, B220, Ter-119, and Gr-1.

Studies reporting positive expression are shown in red; those reporting negative expression are shown in green; and those reporting mixed results are shown in amber. Studies using cells isolated from mice or rats are shown underlined; all other studies used cells isolated from human tissues. Markers are grouped into common expression patterns, as indicated in the right-hand column. Positive or negative expression of some markers is distinctive of more adipogenic ASCs, or of committed preadipocytes, as indicated on the left-hand side. In some studies, it is not clear whether the “ASCs” studied are SVC subpopulations or whole, unsorted SVCs; however, we have tried to distinguish between these two cell populations for each study cited. It should also be noted that much more is probably known about surface marker expression in mature adipocytes; however, we have not included such studies here, inasmuch as this is beyond the scope of the present review. A more-comprehensive version of this table, including many additional surface markers, can be found in supplementary Table I. ISCT, International Society for Cellular Therapy.
receptor-β (PDGFR-β, also known as CD140b) (25). Moreover, the α-SMA+ cells are multipotent in vitro, whereas α-SMA–SVCs are not (25), indicating that ASCs exist within the α-SMA+ population (Fig. 2). Thus, findings from several studies strongly suggest that ASCs are perivascular.

MULTIPOTENCY OF ASCS

In addition to facilitating ASC localization, surface marker expression can also distinguish between functionally distinct SVC subpopulations, and thereby has implications for one of the most important aspects of ASC biology: their capacity to differentiate into multiple cell types. The earliest studies reported in vitro differentiation of human ASCs into cells of mesenchymal origin, such as adipocytes, osteoblasts, chondrocytes, and myocytes (Table 2). Later studies have also used murine ASCs, and have extended this in vitro repertoire to include cells of nonmesodermal origin (Table 2). Generally, these analyses of ASC multipotency are based on morphology or expression of markers characteristic for the various differentiated cell types; in some cases, terminal differentiation is also assessed functionally, for example by contractility of ASC-derived myocytes (125–127), or myelin production from ASC-derived Schwann cells (128). Further research has focused on the ability of ASCs to engraft in host tissues and give rise to these diverse cell types in vivo, often in the context of tissue engineering and regenerative medicine (Table 2). In many cases, differentiation or manipulation in vitro is a prerequisite for ASC engraftment or differentiation in vivo, although this may not be required for all cell fates or tissue types (Table 2). These issues, as related to specific cell or tissue types, are discussed further below.

Adipocytes, osteoblasts, and chondrocytes

Given their adipose origin, it is not surprising that ASCs are capable of forming adipose tissue in vivo (129–131). However, as found for BM MSCs and some committed preadipocyte lines (132–134), this requires the ASCs to be seeded onto polymeric three-dimensional (3-D) scaffolds after adipogenic induction in vitro (129–131). Moreover, at least one study suggests that donor ASCs may contribute to adipose tissue regeneration by stimulating differentiation of host-derived adipocytes (131). More recently, a population of Sca-1+ / CD45–/Mac-1– progenitor cells (called “ScaPCs” for simplicity) with potential for brown adipocyte differentiation has been identified in WAT and skeletal muscle (135). These ScaPC-derived brown adipocytes express traditional brown adipocyte markers such as uncoupling protein-1 (UCP-1) and PRDM16, a transcriptional regulator of brown fat determination that also impacts the thermogenic program of WAT (136–138). In contrast, so-called “brite” (“brown-in-white”) adipocytes that arise in WAT under some conditions express UCP-1 but not PRDM16 (139). Thus, it is unclear whether ScaPCs contribute to formation of brite adipocytes or give rise to a distinct population of brown-like adipocytes in WAT.

ASCs can also form bone and cartilage in vivo (Table 2), with osteogenic capacity similar to that of BM MSCs (74). However, as with adipogenesis, this requires preseeding onto 3-D scaffolds (93, 120, 129, 140, 141) and/or prior differentiation in vitro (85, 129, 142, 143), for example by transfecting the ASCs for stable expression of bone morphogenetic protein-2 (BMP-2) (141) or BMP-4 (120). A related study found that undifferentiated ASCs on 3-D scaffolds could form osteoid in vivo, but this required scaffold-derived BMP-2 release at the site of transplantation (143). Thus, exogenous stimuli such as BMP-2 or -4 seem to be required for effective osteogenesis or chondrogenesis by ASCs in vivo. It should be noted, however, that such exogenous BMP expression also promotes osteoblastogenesis and chondrogenesis by host-derived cells (120), suggesting that the ASC may simply be serving as a gene carrier in these studies. Nevertheless, undifferentiated ASCs can reportedly heal calvarial defects in mice even without exogeneous osteogenic factors (93, 102, 144). In such cases, we postulate that calvarial trauma may induce release of endogenous osteogenic factors, thereby circumventing the need for exogenous stimuli.

Myocytes

Skeletal muscle. In vitro myogenesis of ASCs can be stimulated by coculture with primary myoblasts or myoblast cell lines, with which the ASCs can also fuse (104, 145). Moreover, unsorted or CD34–SVCs are capable of incorporation into damaged skeletal muscle fibers in vivo, thereby contributing to skeletal muscle regeneration (100, 104, 146, 147). However, other studies suggest that ASCs have only limited capacity to form skeletal muscle in vivo (120). This discrepancy probably results from differences in ASC isolation and culture techniques: although long-term passages of CD34–SVCs or pericytes may form myofibers in dystrophic mice (104, 121, 147), ASC myogenic capacity is reportedly lost after expansion in culture and is restricted to CD34–/Sca-1– cells from freshly isolated SVF (104). Given that ASCs probably express CD34 and Sca-1 (Table 1), it is unclear whether they are genuinely myogenic in vivo.

Cardiac muscle. Whole SVC populations can form spontaneously beating cardiomyocytes in vitro after treatment with 5-azacytidine (125) or interleukins (126), and can also express some cardiomyocyte markers in vivo after injection into damaged myocardium (148). However, these observations are based on unsorted murine adipose SCSVs, rather than purified ASC subpopulations. One study suggests that cells isolated from human WAT can form spontaneously contractile cells after exposure to rat cardiomyocyte extracts (149); however, it is unclear whether the cells used in this study were whole SCSVs or a purified subpopulation (Table 2). In contrast, ASCs purified from WAT are unable to undergo 5-azacytidine-induced cardiomyogenesis (150, 151) and only form spontaneously contractile cells through coculture with neonatal rat cardiomyocytes (151, 152). Additionally, the ability of ASCs to repair damaged myocardium after myocardial
Adipose tissue stem cells meet preadipocyte commitment

Both greater cardiomyogenic potential in vitro and ability to promote recovery from myocardial infarction than ASCs from WAT (126, 156). Thus, BAT ASCs may prove more useful than WAT ASCs for treatment of cardiac dysfunction.

Smooth muscle. In addition to skeletal and cardiac myocytes, ASCs can differentiate into smooth muscle, as assessed by marker gene expression and contractility (88, 127, 157). Smooth myocytes thereby derived from human ASCs in vitro are also capable of maintaining smooth muscle function in vivo, as evidenced by their use in tissue engineering of bladder smooth muscle (157).

### TABLE 2. Multipotency of ASCs in vitro and in vivo

| Differentiation in vitro | Differentiation/tissue engraftment in vivo... |
|--------------------------|---------------------------------------------|
|                          | ...after prior differentiation or manipulation in vitro | ...no prior differentiation or manipulation in vitro |
| **White adipocytes/ adipose tissue** | YES (77, 78, 81, 86, 88, 120, 130) | YES (129-131) | NO (129, 130) |
| **Brown adipocytes (with PRDM16 expression)** | ScaPCs (Sca-1+/CD45-/Mac-1-) | YES (133) | |
| **Osteoblasts/bone** | YES (77, 79, 81, 86, 120) | YES (120, 129, 140, 141) | YES (calvarial defects) (93, 102, 144) (exogenous BMP2 in vivo) (133) |
| **Chondrocytes/cartilage** | YES (78, 81, 85, 120, 142) | YES (85, 126, 142) | |
| **Skeletal myocytes** | YES (78, 81, 104, 120, 145) | YES (100) | SVCs (unsorted; in damaged muscle) (104, 146, 147) |
| **Cardiomyocytes** | YES (88, 127, 157) | YES (157) | |
| **Smooth myocytes** | YES (ASCs (CD45-; but limited potential for hematopoiesis) (122-160) | YES (ASCs (CD45+/CD31-) HS) (161) | NO (161) |
| **Hematopoietic cells** | NO (ASCs (CD45+)) (97, 109, 160, 162, 163) | NO (ASCs (CD45-)) (98, 163) | YES (91, 166, 167) |
| **Endothelial cells** | YES (81, 84, 88, 91, 94, 95, 128, 164) | YES (165) | |
| **Neural cells** (e.g., neurons and glia) | NO (87, 122) | YES (122, 172, 173, 175) | YES (with prior liver injury) (87, 174) |
| **Epithelial cells** (e.g., retinal pigment epithelium) | YES (87, 122) | YES (122, 172, 173, 175) | |
| **Hepatocytes** | YES (122, 178) | YES (ASCs with exogenous Pdx1 expression) (103, 179) | |
| **Pancreatic β-cells** | YES (122, 178) | YES (ASCs with exogenous Pdx1 expression) (103, 179) | |
| **Dental bud** | YES (SVGS (CD14-)) (170) | YES (170) | |

Some cell fates are only possible with particular precursor cell populations, e.g., whole, unsorted SVCs or subpopulations of ASCs defined by surface markers, as indicated. For assessment of ASC differentiation in vivo, numerous studies have shown that donor ASCs can engraft into host tissues, but differentiation into tissue-specific cell types has not always been demonstrated. However, for simplicity, we combine engraftment and in vivo differentiation into the same categories. Additionally, in most cases, differentiation in vivo requires prior manipulation (e.g., transduction for exogenous gene expression or coculture with other cell types) or differentiation in vitro. Nevertheless, in vivo differentiation of nondifferentiated ASCs has been reported, often in the context of host tissue injury, as indicated. As in Table 1, studies using cells isolated from mice or rats are shown underlined, whereas those based on human cells are not.

Infarction may be a result of stimulation of neovascularization by ASCs, rather than formation of ASC-derived cardiomyocytes (153, 154). Thus, no studies have convincingly demonstrated that purified WAT ASCs are capable of forming functional cardiomyocytes in vivo. However, SVCs from brown adipose tissue (BAT) may be better suited to this purpose. Our lab has demonstrated that BAT SVCs have intrinsic cardiomyogenic potential that is enriched in subpopulations expressing Sca-1 or c-kit (155). Moreover, this cardiomyogenic potential is enhanced by treatment with Wnt5a, a noncanonical Wnt ligand, or with DKK1, an inhibitor of canonical Wnt signaling (155). Interestingly, precursors from BAT show both greater cardiomyogenic potential in vitro and ability to promote recovery from myocardial infarction than ASCs from WAT (126, 156). Thus, BAT ASCs may prove more useful than WAT ASCs for treatment of cardiac dysfunction.

Smooth muscle. In addition to skeletal and cardiac myocytes, ASCs can differentiate into smooth muscle, as assessed by marker gene expression and contractility (88, 127, 157). Smooth myocytes thereby derived from human ASCs in vitro are also capable of maintaining smooth muscle function in vivo, as evidenced by their use in tissue engineering of bladder smooth muscle (157).
Hematopoietic and endothelial cells

Two studies have suggested that ASCs can form hematopoietic cells in vivo (158, 159), albeit without the self-renewal capacity characteristic of genuine HSCs (66). However, each of these reports used whole SVCs, which include cells expressing the hematopoietic marker CD45 (Table 1); in contrast, MSCs and ASCs are CD45− (Table 1 and see Ref. 116). Although the CD45− fraction of SVCs may be capable of limited hematopoiesis and endothelial activity (160), most evidence suggests that CD45− ASCs are incapable of hematopoiesis in vitro or in vivo (120, 161).

Related studies have investigated endothelial cell differentiation of ASCs. CD34+ subsets of SVCs (CD34+/CD31− and CD34+/CD90+) are capable of generating endothelial cells in vitro, with formation of tube-like structures and up-regulation of the endothelial progenitor cell marker Flk-1 sometimes apparent (22, 97, 109, 162, 163). In contrast, CD34− SVCs are unable to form endothelial cells (98, 163). In vivo, both unsorted SVCs and purified ASCs can promote neovascularization of host tissues (97, 109). This effect may occur largely through ASC/SVC-derived release of factors such as VEGF, thereby stimulating angiogenesis by host endothelial cells (22, 98, 109, 154). However, donor ASCs may also form functional vasculature in vivo (97, 109) that can reportedly connect with host blood vessels (107).

Ectodermal cells

Neural cells. In addition to mesodermal fates, in vitro differentiation of ASCs into neural cell types has long been reported (Table 2). However, this is largely based on morphology or limited expression of typical neural markers, such as nestin, NeuN or GFAP (81, 91, 95, 164); although ASC-derived Schwann-like cells can produce myelin structures during in vitro coculture (128), few reports have demonstrated any responsiveness to neurotransmitters or electrophysiological activity (84, 94). Indeed, it has recently been suggested that murine ASCs are unable to form functional neurons (165). Nevertheless, an earlier study found that human ASCs can home to injured brain regions and improve ischemia-induced neurological defects (91), and more-recent reports demonstrate the potential for murine ASCs to enhance neuronal regeneration (166, 167). Thus, ASCs may hold promise for the treatment of neural defects.

Epithelial cells and dental bud. SVCs lacking CD34 can form epithelial cells in vitro in response to all-trans retinoic acid (47). A related study shows that ASCs can differentiate in vitro into cells resembling retinal pigment epithelial cells, with the ability to form pigmented granula (168). Moreover, CD34− SVCs can engraft into retinas in a model of diabetic retinopathy (169), suggesting another potential therapeutic application of these cells. Another ectodermal fate was recently reported by Ferro et al., who show that CD34− SVCs form dental bud-like structures under prolonged 3D culture in vitro (170). However, as mentioned above and discussed later, ASCs are probably CD34+; hence, no studies have conclusively shown that ASCs can form epithelial cells (Fig. 2).

Endodermal cells

Hepatocytes. ASCs can undergo hepatic differentiation in vitro, as assessed by morphology, gene expression, and functional assays such as LDL uptake, urea production, and glycogen storage (87, 171–173), and this may be enhanced in a CD105+ subpopulation of SVCs (172). These ASC-derived hepatocytes can also engraft into livers and reconstitute some hepatocyte functions in immunodeficient mice, often after induction of liver injury (87, 175–175). Although prior hepatic differentiation in vitro enhances hepatic ASC engraftment in vivo (173), undifferentiated ASCs are also capable of hepatic engraftment (87, 174). Thus, prior in vitro manipulation is not absolutely required for ASCs to differentiate into some cell types in vivo (Table 2). However, it is not clear whether the hepatocytes derived from ASCs in vivo are generated through genuine hepatic differentiation or simply by fusion of the ASCs with host cells in the liver, as reported for BM MSCs (176, 177). Nevertheless, human ASCs are currently under investigation as a treatment for liver injury (175).

Pancreatic islet cells. Finally, ASCs may be able to differentiate into pancreatic cell types, with specific culture conditions promoting expression of insulin, glucagon, and other pancreatic genes in vitro (178). ASCs can also engraft into the pancreas, acquire a β-cell phenotype, and restore pancreatic function in vivo in diabetic animals, albeit only after prior transduction for exogenous Pdx1 expression (101, 179). Thus, while it is unlikely that unmodified ASCs are similarly capable of functional islet cell formation, they may be useful therapeutically in this context.

Multipotency of mature adipocytes

While most researchers currently agree that multipotent ASCs are derived from the SVF of adipose tissue, more-controversial studies report that mature adipocytes also possess multidifferentiation potential. Adipocytes isolated from murine or human WAT can be “de-differentiated” through ceiling culture, whereby the floating, lipid-laden adipocytes adhere to the top of culture vessels that are filled with culture medium; subsequently, the adipocytes lose lipid, adopt a fibroblast-like morphology, and begin to undergo cell division (180–182). Importantly, these studies appear to exclude the possibility that the dedifferentiated adipocytes are simply derived from residual SVCs, which have been noted to persist among the floating adipocyte layer following collagenase digestion of WAT (7). As for ASCs, the proliferative, dedifferentiated adipocytes can form adipocytes, osteoblasts, chondrocytes, and cardiomyocytes in vitro (180–182). They also exhibit some capacity for in vivo osteoblastogenesis or cardiomyogenesis following subcutaneous implantation into NOD/SCID mice (182) or injection into damaged myocardium (183), respectively. Additionally, these dedifferentiated adipocytes express cell surface markers similar to those of preadipocytes and ASCs (Table 1 and supplementary Table I), including CD13, CD29, CD44, CD90, CD105, and CD49d, but not CD31 (181). Thus, murine and human adipocytes can dedifferentiate into ASC-like cells, at least in vitro.
Multidifferentiation potential of ASCs: nature or nurture?

The ability to differentiate ASCs into numerous cell types clearly holds enormous therapeutic potential. However, what this tells us about the role of ASCs in more biological contexts is less certain. Though SVCs or ASCs are often capable of tissue engraftment or differentiation into some cell types in vivo, in many cases it is unclear whether these donor-derived cells can actually perform or maintain cell type-specific functions in this context, as reported for whole blood reconstitution by HSCs (66). Moreover, despite reported maintenance of ASC multipotency after extended passaging in vitro (21, 121, 147, 185), whether ASCs are capable of true self-renewal in vivo remains poorly understood. Thus, whether ASCs are bona fide stem cells is still a matter of debate.

THE ASC MEETS PREADIPOCYTE COMMITMENT

While the stem cell nature of ASCs remains controversial, the fact that WAT contains committed preadipocytes stands unrefuted. However, the great advances in our knowledge of terminal adipocyte differentiation (53–57) have occurred against a backdrop of relative ignorance regarding both the identity of committed preadipocytes and mechanisms regulating preadipocyte commitment (186). Given that both ASCs and committed preadipocytes are subpopulations of WAT SVCs, it is perhaps unsurprising that progress in our understanding of ASC biology has also shed light on preadipocyte commitment.

Preadipocyte commitment: scratching the surface

Among the many surface markers investigated in ASCs, perhaps the most informative with regard to preadipocyte commitment is CD34. The CD34 family (CD34, podocalyxin, and endoglycan) comprises single-pass transmembrane glycoproteins of the sialomucin family that can potentially impact cell adhesion, proliferation, migration, and differentiation (187). CD34 expression is most commonly noted on hematopoietic progenitor cells and vascular tissue, but has also been observed on various other cell types (187). Although CD34 expression is a classic marker of an active self-renewing HSC population (188), BM MSCs (72, 116, 119), embryonic stem cell-derived MSCs (Paul Krebsbach, personal communication) and pericytes (23, 121) are thought to be CD34−. Findings for CD34 expression in ASCs have been inconsistent (Table 1), possibly due to progressive downregulation of CD34 in culture (88, 103, 119, 120) or the relatively weak expression of CD34 in Lin− stroma. Nevertheless, CD34 appears to distinguish between different functional subgroups of ASCs, especially with regard to adipogenesis: although CD34− SVCs can undergo adipogenesis (47, 121, 123), CD34+ cells make up approximately 82% of the SVF (106) and are consistently more adipogenic in vitro than CD34− populations after negative selection for CD31 (124, 161, 189). Similarly, exclusion of CD34+ cells in muscle regeneration studies inhibits ectopic adipose formation both in vitro and in vivo (190), indicating that CD34− cells are incapable of adipogenesis. Finally, adipocytes isolated from WAT are noted as CD34+ (106). Thus, CD34+/CD31− appears to define a population of robustly adipogenic ASCs in vitro and to distinguish adipogenic progenitors in vivo. Further refinement of the adipogenic ASC population has been made based on CD105 expression. One study found that in whole SVCs, cells expressing CD105 are more adipogenic than unsorted SVCs (172). In contrast, within the CD34+/CD31− subpopulation, the ability to undergo adipogenesis is restricted to CD105− cells (161).

Based on these observations, one might predict committed preadipocytes to also be CD34+/CD31−/CD105−. In 2008, an elegant study by Rodeheffer, Birsoy, and Friedman showed this to indeed be the case (189). In an approach reminiscent of some studies of ASC multipotency, they used FACS to isolate distinct subpopulations of SVCs, first assessing the multipotency of each population in vitro. This revealed that in vitro formation of adipocytes, chondrocytes, osteoblasts, or myocytes is restricted to Lin−/CD34+/CD29+ SVCs, which strongly supports independent assertions that ASCs are CD34+ (22, 109, 118, 161). Further separation of the Lin−/CD34+/CD29+ SVCs based on Sca-1 and CD24 revealed a striking result: although Lin−/CD29+/CD34+/Sca-1+/CD105−/CD117− SVCs are capable of in vitro adipogenesis regardless of CD24 status, only the CD24+ population can reconstitute WAT in lipodystrophic mice (189). Importantly, this WAT reconstitution was associated with decreased serum glucose and insulin and was maintained in the host mice for at least 12 weeks. Thus, Lin−/CD29+/CD34+/Sca-1+/CD105−/CD117−/CD24+ SVCs are capable of long-term reconstitution of functional WAT in vivo, strongly suggesting that these markers are expressed on committed preadipocytes (Table 1 and Fig. 2). However, given that this SVC subpopulation is also capable of osteoblastogenesis, chondrogenesis, and myogenesis in vitro (189), additional factors must further distinguish committed preadipocytes from multipotent cells within this subpopulation.

In a related study, Tang et al. used lineage tracing to identify committed preadipocytes based on expression of PPARγ2 (24), a transcription factor that is essential for adipogenesis and adipocyte function (53, 54, 191–193). Perhaps unsurprisingly, they found that SVCs with expression of PPARγ (PPARγ+) are more adipogenic in vitro than PPARγ− SVCs, and are also capable of adipocyte formation in vivo (24). In a clever twist, their system was also made doxycycline-sensitive, which allows the formation of
PPARγ-expressing progenitors in WAT to be temporally assessed. This revealed that these PPARγ+ SVCs proliferate in vivo. Therefore, these findings suggest that among whole WAT SVCs, committed preadipocytes are distinguished by their expression of PPARγ and that these preadipocytes self-renew through proliferation (Fig. 2). FACS analysis of surface markers revealed that the PPARγ+ SVCs express Sca-1 and CD34, but not CD105, CD45, Ter-119, or Mac-1 (also called CD11b). This pattern is consistent with the aforementioned findings for adipogenic ASCs and committed preadipocytes (Table 1). Importantly, SVCs isolated based on these markers, but independently of PPARγ-expression, were also capable of in vivo adipogenesis (24). These data suggest that, in addition to being Sca-1+, CD34+, CD105−, and CD24+, committed preadipocytes can be distinguished among whole WAT SVCs by their expression of PPARγ (Fig. 2).

**Committed preadipocytes are perivascular cells**

Decades of histological studies have suggested a close association between the vasculature and adipocyte progenitors (18, 20, 194) (Fig. 1); hence, the possibility that preadipocytes derive from pericytes has long been proposed (20). The more-recent progress in ASC characterization further supports this possibility. As discussed above, CD34+/CD31− ASCs are capable of both endothelial and adipocyte differentiation (22, 109, 124, 161, 189). This suggests that adipocytes and vascular endothelial cells may share a common origin and is therefore consistent with the notion of preadipocytes as perivascular cells. However, the 2008 study by Tang et al. was the first to provide convincing evidence of this. They found that PPARγ-expressing SVCs (i.e., committed preadipocytes) also express the pericyte markers α-SMA, PDGFR-β (CD140b), and NG2 (chondroitin sulfate proteoglycan) (Fig. 2), and that these cells localize around tube-like structures in WAT (24). Additional lineage tracing revealed that adipose tissue derives from PDGFR-β-expressing cells, and that PDGFR-β+ SVCs isolated from WAT can form adipocytes in vivo (24). Thus, like ASCs, committed preadipocytes appear to be perivascular in WAT. Though this perivascular nature has also been noted for brown adipocyte progenitors (195), pericytes are PPARγ– in the liver and skeletal and cardiac muscles, kidney, retina, pancreas, spleen, and lung (24). This observation suggests, quite logically, that pericytic preadipocytes may exist only in adipose tissues.

Finally, it is worth noting that PPARγ or PDGFR-β alone is not sufficient to identify committed preadipocytes: PPARγ-expressing cells from aged muscle cannot undergo adipogenesis in vitro and, whereas PDGFR-β+ SVCs from WAT can form adipocytes in vivo, those from muscle, kidney, or heart cannot (24). These observations suggest that additional mechanisms are involved in commitment of preadipocytes around the vasculature of WAT.

**Below the surface: transcriptional regulators of ASCs and committed preadipocytes**

Although the transcriptional regulation of adipogenesis is extremely well characterized (53, 54, 56, 57), how transcription factors impact ASC biology or preadipocyte commitment remains poorly understood. This is especially true for ASCs. One earlier microarray analysis was limited to angiogenic and extracellular matrix genes (108), whereas another focused on gene expression during adipogenesis or osteoblastogenesis (110). A more-recent microarray study compared transcriptional profiles of human ASCs, BM MSCs, and stem cells from umbilical cord, identifying gene expression signatures distinct to each stem cell type (111). However, these studies have not been followed by any comprehensive mechanistic analysis. In contrast, progress has recently been made for committed preadipocytes. Work from the Spiegelman lab identified both PPARγ2 and zinc-finger protein 423 (Zfp423) as transcription factors that are enriched in adipogenic fibroblast cell lines, relative to nonadipogenic cells (196). Enrichment of PPARγ2 supports the notion of PPARγ as a marker of preadipocytes (24); however, Zfp423 had not previously been reported in this context. Although Zfp423 is not upregulated during adipogenesis, exogenous expression of Zfp423 in otherwise nonadipogenic cells is sufficient to specifically upregulate PPARγ2 and markedly increases the adipogenic potential of these cells (196). Conversely, in vitro adipogenesis is impaired in 3T3-L1 preadipocytes or mouse embryonic fibroblasts with stable knockdown or total knockout of Zfp423, respectively. These observations identify Zfp423 as a transcriptional regulator of preadipocyte commitment (Fig. 2).

More-recent work identifies the related transcription factor Zfp467 as another potential regulator of preadipocyte commitment (197). Like Zfp423, exogenous expression of Zfp467 sensitizes cells to adipogenic stimuli and upregulates expression of PPARγ and adipopectin, but, unlike Zfp423, exogenous Zfp467 also enhances expression of C/EBPα (197), another transcription factor that plays a key role in adipogenesis (53, 54, 56, 57). Conversely, knockdown of Zfp467 decreases expression of these adipocyte genes and impairs adipogenesis, similar to the findings for Zfp423. Thus, Zfp467 may also affect preadipocyte commitment on a transcriptional level.

The studies from the Spiegelman and Graff labs further investigated gene expression signatures of committed preadipocytes using transcriptional profiling. Thus, Tang et al. found that PPARγ+ SVCs are transcriptionally distinct from both adipocytes and PPARγ− SVCs; specifically, they found that Gsc, Twist2, Mmp3, Egfr, and Fgf10 are enriched in the PPARγ+ SVCs (24) (Fig. 2). Spiegelman’s Zfp423 study transcriptionally profiled adipogenic and nonadipogenic fibroblasts, revealing numerous differentially expressed genes. Examples include Pdgfrα (aka CD140a; Table 1), Hmx1, and Pou3f3, which are enriched in nonadipogenic cells; and Efemp1, Lgals3, Lggbp4, and Lpl, which are enriched in adipogenic cells (Fig. 2) (196). Clearly, future investigation of these genes, in both murine and human cells, may further improve our understanding of the mechanisms underlying preadipocyte commitment.

**Mechanisms of preadipocyte commitment**

With our increased knowledge of surface markers, perivascular localization, and gene expression, the identity of
Both ASCs and committed preadipocytes is coming into clearer focus. But further light is shed on ASC biology and preadipocyte commitment by drawing comparisons across these studies. For example, are Zip423, Zip467, or other putative marker genes of committed preadipocytes also enriched in adipogenic ASCs or in the Lin−/CD29+/CD34+/Sca-1+/CD105−/CD117−/CD24+ population identified by Rodeheffer, Birsoy, and Friedman? And do SVCs that express these preadipocyte markers localize perivascularly in WAT, as reported for PPARγ-expressing SVCs? It is worth noting that not all pericytes in WAT express PPARγ (24), which indicates that only a subset of pericytes are committed preadipocytes. This could explain disparate findings in other studies, which variously describe pericytes as CD34− (49, 121, 124) or CD34+ (22). Given that CD34 expression is variable in ASCs (Table 1) but that committed preadipocytes are CD34+, it is possible that increased expression of CD34 may facilitate the commitment of preadipocytes (CD34+) from perivascular ASCs (CD34−; Fig. 2), possibly by promoting migration of CD34−ASCs from the tunica media to the adventitia of blood vessels (23).

Comparing reported surface markers of preadipocytes with those of ASCs (Table 1) reveals many other possibilities. If committed preadipocytes are Lin−/CD29+/CD34+/Sca-1+/CD105−/CD117−/CD24+, what does this tell us about the formation of these cells from the heterogeneous SVC population, presumably via perivascular ASCs (Fig. 2)? The Lin (lineage) antigens comprise CD2, CD3, CD4, CD5, CD8, NK1.1, B220, Ter119, and Gr-1 (Table 1). Whole SVF contains some Lin+ cells, whereas ASCs are reportedly Lin− (98). This suggests that lack of Lin expression distinguishes both ASCs and committed preadipocytes from the general SVC pool. A similar pattern exists for the endothelial cell marker CD31 (Table 1). Interestingly, endothelial cells have been shown to suppress adipogenesis of human SVGs by secreting Wnt ligands (198), which are well-established inhibitors of both white and brown adipocyte differentiation (55, 199–203). Therefore, we postulate that negative selection for CD31 may enhance ASC adipogenesis by removing endothelial cells and thereby reducing the anti-adipogenic effects of Wnt ligands. In contrast to Lin and CD31, both CD29 (aka β1-integrin) and Sca-1 are expressed in BM MSCs, whole SVCs, and ASCs (Table 1), demonstrating that neither is restricted to committed preadipocytes. However, the number of adipocyte progenitors in BM is significantly reduced in Sca-1-null mice (204). Thus, unlike many other markers, the Sca-1 antigen itself has been implicated as a regulator of preadipocyte commitment, at least in mice.

Among all the reported surface markers, only CD105 and CD140a appear to be differentially expressed, consistently, between ASCs and committed preadipocytes (Table 1). The enhanced adipogenic capacity of CD105−ASCs (161) suggests that downregulation of CD105 may be a functional requirement for preadipocyte commitment. A potential mechanism becomes apparent when the function of this protein is considered: CD105, also called endoglin, forms part of the TGF-β receptor complex. Numerous studies demonstrate that TGF-β inhibits adipogenesis, probably through activation of the transcriptional regulator Smad3 (205–207). Moreover, the cell surface availability of TGF-β receptors decreases during adipogenesis in vitro (207). Therefore, we postulate that downregulation of CD105 may enhance ASC adipogenesis and facilitate preadipocyte commitment by decreasing TGF-β signaling in these cells. Similarly, CD140a is better known as PDGFRα; hence, given that PDGF suppresses adipogenesis and PPARγ activity (208–211), decreased PDGFRα expression in committed preadipocytes (Table 1) may be obligatory for preadipocyte commitment (Fig. 2). However, other studies find that PDGFRα expression is enriched in more-adipogenic subpopulations of some cell types, including MSCs derived from mouse embryonic stem cells (212) or skeletal muscle (213). This is similar to the aforementioned finding that PDGFR-β-expressing SVCs are adipogenic (24). Finally, a recent study shows that in mice, expression of PDGFA is enriched by 100-fold in preadipocytes relative to SVCs (214). These observations question the notion of PDGF as an inhibitor of adipogenesis and underscore the need for further investigation of PDGF ligands and receptors in regulating preadipocyte commitment.

Although TGF-β inhibits adipogenesis, other members of the TGF-β superfamily, namely BMP-2, BMP-4, and BMP-7, stimulate commitment toward the white or brown adipocyte lineages. This observation is based largely on studies in the C3H10T1/2 MSC line, which can differentiate into adipocytes, osteoblasts, chondrocytes, and myocytes (215, 216). For example, BMP-7 pretreatment induces expression of UCP-1 both in C3H10T1/2 MSCs and in brown preadipocytes, and BMP-7-treated C3H10T1/2 MSCs have an enhanced capacity to form BAT after implantation into athymic mice (217). Compellingly, both total BAT mass and UCP-1 expression are reduced in perinatal BMP-7 knockout mice, whereas adenoviral expression of BMP-7 in wild-type mice increases BAT mass and whole-body thermogenesis (217). Thus, BMP-7 can augment BAT function both by driving commitment of MSCs to the brown adipocyte lineage and by enhancing adipogenesis of committed brown preadipocytes. Although BMP-2 and -4 also stimulate lipogenesis in brown preadipocytes, they do not induce UCP-1 expression in these cells (217). Indeed, these BMPs are more strongly implicated as positive regulators of white preadipocyte commitment (Fig. 2). For example, treatment of C3H10T/12 MSCs with BMP-4, prior to adipogenic induction, upregulates expression of PPARγ and dose-dependently enhances subsequent adipogenesis, both in vitro after exposure to adipogenic stimuli and in vivo after implantation into athymic mice (218). BMP-2 similarly enhances C3H10T1/2 adipogenic commitment, albeit less potently than BMP-4 (219–221). It is worth noting that effects of BMP-2 on cell fate are dose-dependent, with lower concentrations favoring adipogenesis but higher concentrations favoring osteoblast or chondrocyte differentiation (219). This could explain why exogenous BMP-2 can promote osteoblastogenesis or chondrogenesis by ASCs, as mentioned above. Mechanistically, BMP-2 and -4...
promote preadipocyte commitment by signaling through type 1a and type 2 BMP receptors (BMPr1a and BMPr2) to phosphorylate and activate Smads 1, 5, and 8, which each function as heterodimers with Smad4 (221). Indeed, BMP-2 stimulates binding of Smad1/4 heterodimers to the promoter of the PPARy2 gene (222), and RNAi-mediated knockdown of Smad4 prevents BMP-2-induced preadipocyte commitment (221).

Mechanisms through which Smads might exert these effects are also coming into focus. For example, Zfp423 contains a Smad binding domain and is a BMP-dependent transcriptional coactivator of Smad proteins (223). As such, expression of Zfp423 sensitizes NIH3T3 cells to the preadipogenic effects of BMP-2 or BMP-4, but only when the Smad binding domain is intact (196). Another zinc finger protein, Schnurri-2, also binds directly to Smad1/4 heterodimers in response to BMP-2 stimulation. This Schnurri-2/Smad1/Smad4 complex thereby acts synergistically with C/EBPα to activate PPARy expression downstream of BMP-2 (222). In addition to PPARy, another transcriptional target of Smad1/4 that is important for preadipocyte commitment is lysyl oxidase (Lox). Both BMP-2 and BMP-4 increase Lox expression in a Smad4-dependent manner, and knockdown of Lox impairs BMP-2-induced commitment of C3H10T1/2 MSCs (221). Lox knockdown also blocks adipogenesis of murine embryonic fibroblasts, even in the absence of ectopic BMPs (221). These observations identify Lox as another positive regulator of preadipocyte commitment (Fig. 2) and indicate that endogenous BMP activity is also important for this process. Indeed, expression of BMP-4, BMPr2, BMPr1a, and Smads 1, 4, 5, and 8 is elevated in a subline of C3H10T1/2 MSCs that has increased adipogenic potential (220), and exogenous expression of BMPr1a promotes commitment of MSCs even in the absence of ectopic BMP-2 or -4 (221). These observations underscore the importance of BMP2/4, Smad1/4/5/8, and Lox as positive regulators of white preadipocyte commitment (Fig. 2), at least in mice. This suggests that expression of these factors may be enriched in adipogenic ASC subpopulations or in the Lin−/CD29+CD34+/Sca-1+/CD105−/CD117−/CD24+ population of committed preadipocytes. Future studies should explore these possibilities and further investigate whether these mechanisms also impact preadipocyte commitment in humans.

Fibroblast growth factor (FGF) may be another positive regulator of preadipocyte commitment. Microarray analysis reveals that FGF2, FGF6, and FGF7 are among the most highly expressed genes in human ASCs (108) (Fig. 2). Interestingly, culture of rat BM MSCs or human ASCs in the presence of FGF2 prior to adipogenic induction upregulates expression of PPARy and enhances subsequent adipogenesis (224, 225). Indeed, exogenous FGF2 facilitates in vivo WAT formation by isolated human SVCs (226). These observations are reminiscent of effects of BMP-2 and BMP-4 and support the possibility that FGF may promote commitment from ASCs to preadipocytes (Fig. 2).

A final marker that must be considered is CD24. To our knowledge, no studies have reported CD24 expression status in ASCs (Table 1). Given that only a small population of SVCs express CD24 (189), it is likely that ASCs studied thus far are largely CD24−. This could explain the relatively poor adipogenic capacity of ASCs, which require prior adipogenic induction to form adipocytes in vivo (129–131). The unique ability of CD24 expression status to distinguish between SVC adipogenic capacity in vivo clearly warrants further investigation. For example, does CD24 status also distinguish between other preadipocyte markers, such as PPARy or Zfp423? And are all of the adipogenic Lin−/CD29+/CD34+/Sca-1+CD105−/CD117−SVCs perivascular, or are there differences in localization of the CD24+ and CD24− subpopulations? Knowledge of the function of CD24 may provide further clues. CD24 is a GPI-linked sialoglycoprotein that was initially characterized as related to B lymphocytes and hematopoietic lineages (227, 228). In relation to adult stem cells, positive selection for CD24 facilitated regeneration of a mouse mammary gland in vivo from a single cell (229), and CD24 has recently gained prominence as a marker of cancer stem cells. Here, CD24 expression has been linked to metastatic progression, thereby making CD24 a putative therapeutic target (230). The relationship between CD24 and metastasis probably relates to the ability of CD24 to facilitate interactions with the vasculature. This ability of CD24 to alter adhesive properties may also explain why putative stem cells expressing CD24 have the ability to engraft and reconstitute diverse organ systems, whereas those lacking CD24 do not (231). However, current knowledge provides no clues to the mechanisms through which CD24 might impact adipogenesis. Clearly, further exploration of the relationship between CD24 expression, stem cell engraftment, and preadipocyte commitment is warranted.

Compared with SVCs and ASCs, very little is known about surface marker expression on committed preadipocytes (Table 1 and supplementary Table I). But even less is known about these cell types on a global level. Future studies should attempt global characterization of these cells, from both murine models and humans, for example through RNA sequencing, proteomics, and large-scale epigenetic analyses. This information would allow far more extensive comparisons to be drawn between SVCs, ASCs, and committed preadipocytes, which almost certainly will provide many additional insights into the mechanisms that underlie preadipocyte commitment.

Beyond adipose tissue: potential origins of ASCs

The notion of ASCs and committed preadipocytes as perivascular cells raises the possibility that precursors for these cells might derive from outside adipose tissue. One study found that fibrocytes, a subset of peripheral blood mononuclear cells, can undergo adipogenesis in vitro and can form adipocytes in vivo after reimplantation into SCID mice (232). Several other studies have transplanted BM from GFP-expressing donors into wild-type recipients to investigate whether BM-derived cells might home through the vasculature to form adipocytes in WAT. For example, following such a transplant, Klemm and colleagues detected GFP+ multilocular adipocytes in WAT, the presence of which is enhanced by high-fat diet feeding or treatment.
with rosiglitazone, a PPARγ agonist (233). Based on these observations, the authors concluded that adipocytes can indeed derive from BM in adult mice. Because there is no evidence that BM MSCs enter the circulation, these authors postulated that the GFP+ multilocular adipocytes may derive from donor HSCs. In a subsequent study, they addressed this possibility by transplanting BM that had been selected for MSCs or HSCs based on CD45 expression (CD45− or CD45+, respectively). They found that donor-derived adipocytes are only detectable after transplantation of CD45+ BM (234). This suggests that CD45+ HSCs can give rise to adipocytes, a possibility that is supported by one independent study (235). In additional lineage tracing experiments using mice in which LacZ expression is restricted to the myeloid lineage, LacZ+ adipocytes were detectable in WAT (234). This observation further suggests that adipocytes can derive from myeloid progenitor cells even beyond the context of BM transplantation. However, these findings remain controversial. For example, Koh et al. also detected GFP+ cells in WAT following BM transplantation; however, they found that these GFP+ cells do not express the adipocyte markers perilipin or adipophilin, whether under conditions of normal diet, high-fat diet, rosiglitazone treatment, during WAT regrowth following lipectomy, or even in a parabiosis model between GFP+ and GFP− mice (236). Instead, the GFP+ cells in WAT express macrophage markers, such as CD11b and CD45 (236). An independent study also showed that the majority of BM-derived GFP+ cells in WAT are CD45+, and that ASCs isolated from these WAT depots and differentiated into adipocytes in vitro do not express GFP (237). These findings suggest that the donor BM-derived, multilocular cells that engraft in WAT are not bona fide adipocytes. Indeed, data overwhelmingly establish ASCs and committed preadipocytes as CD45−/CD11b− (Table 1 and supplementary Table I; Fig. 2), which is inconsistent with the observation that committed preadipocytes in craniofacial WAT depots may derive from neural crest (Fig. 2), this is not the case for ASCs and adipocytes in most other adipose depots.

**ASCs and preadipocytes in health and disease**

As discussed above, decades of research have shown that factors such as WAT depot, aging, or obesity can dramatically impact adipogenesis in whole SVC populations. Whether these factors affect ASC multipotency or specific preadipocyte subpopulations is only beginning to be established. Although aging clearly impairs the adipogenic capacity of SVCs (above), it does not affect ASC function (172, 239). In contrast, obesity does appear to impact ASC biology. For example, the proportion of adipogenic CD34+/CD31− SVCs in subcutaneous WAT (scWAT) positively correlates with body mass index in nonobese individuals (97, 161), suggesting that nutritional signals might stimulate preadipocyte commitment. In contrast, the number of committed preadipocytes in scWAT declines in obesity (240). Thus, obesity may exhaust the capacity for preadipocyte self-renewal, consistent with the hypothesis that impaired adipose tissue expandability contributes to obesity-associated metabolic dysregulation (241). This possibility is especially interesting in light of recent findings about thiazolidinediones (TZDs), synthetic PPARγ ligands that have been used as anti-diabetic drugs; chronic TZD treatment reportedly decreases the adipogenic capacity of ASCs, thereby exhausting the pool of committed preadipocytes in WAT (242). Other studies have investigated the effects of obesity on more-distinct SVC subpopulations. For example, brown adipogenesis by ScaPCs is enhanced in obesity-resistant mice (135). Thus, differences in propensity for brown adipogenesis might impact obesity susceptibility.

Depot-specific differences in ASCs are also emerging. For example, ASCs isolated from visceral WAT are more osteogenic than those from scWAT (243), but have a lesser potential for brown adipogenesis than scWAT ASCs (135). These differences could be explained by an increased proportion of committed preadipocytes in scWAT. Indeed, one report finds that SVCs from scWAT contain more CD34+ cells than SVCs from visceral WAT (97); however, this has not been observed in all studies (106, 244). Even the precise location of scWAT can impact resident ASC biology, with abdominal scWAT containing a greater percentage of ASCs than that from the hip/thigh; however, neither ASC proliferation, osteogenesis, or chondrogenesis differs between these scWAT depots (245). Similarly, WAT depot reportedly does not affect ASC myogenesis (104, 244) or secretion of angiogenic or proinflammatory proteins (244). Transcriptional profiling has revealed further depot-specific differences in preadipocyte gene expression (246, 247). These differences are maintained in clonal preadipocyte cultures over 40 population doublings (247), which suggests that epigenetic modifications may contribute to depot-specific variation in preadipocyte phenotypes. A comparison of these transcriptional profiles with putative markers of committed preadipocytes is clearly warranted.
BROADER QUESTIONS

Although the past decade has witnessed enormous advances in our knowledge of both ASCs and committed preadipocytes, numerous questions remain. A major unresolved issue is whether ASCs are genuine stem cells, which remains questionable owing to lack of conclusive evidence for their ability to undergo self-renewal or to uniformly reconstitute all mesodermal lineages in vivo. Similar questions have been raised for BM MSCs, despite their ability to home from the BM to various extramedullary mesenchymal tissues (69, 73). ASCs isolated ex vivo can also engraft into multiple extramedullary tissues after host injection (248, 249); however, whether this is also true for ASCs within WAT remains unknown. It would be far more informative to transplant whole fat pads from luciferase-expressing mice to WT recipients, followed by analysis of luciferase activity in nonadipose tissues. This would reveal whether ASCs are capable of moving from their resident tissue to other tissue types, as evident for BM MSCs or HSCs.

But even this approach has drawbacks. Numerous studies have shown that tissue engraftment or differentiation of implanted ASCs/SVCs into other cell types in vivo requires specific conditions, such as prior tissue injury (87, 91, 97, 157, 174, 250, 251) or use of immunodeficient mice as recipients (e.g., SCID mice) (87, 120, 173). Indeed, even SVC subpopulations containing committed preadipocytes can only reconstitute WAT under conditions that favor new WAT formation, such as genetic lipodystrophy or high-fat diet (189). Therefore, migration of ASCs from WAT and subsequent engraftment in other tissues might require some type of injury or other intervention posttransplant. These observations highlight the importance of the host tissue when assessing in vivo ASC multipotency: how do local tissue environments impact multipotent cell fate to promote the differentiation of cell types specific to those tissues? And how do these mechanisms vary under different physiological or pathophysiological conditions? The importance of host tissue environment also highlights a drawback to current analyses of ASC differentiation in vivo, in that the ability or inability of ASCs to form certain cell/tissue types under particular experimental conditions may not accurately reflect their actual multilineage capacity in different physiological or pathophysiological contexts. More-refined lineage tracing, for example based on Zfp423 or multiple other markers, would further facilitate the identification of ASC-derived cells in vivo.

In addition to these questions about terminal fates of ASCs, there is also uncertainty about their relationship to preadipocytes. Although preadipocytes are clearly a distinct subpopulation of SVCs, differences between ASCs and preadipocytes are less marked (Table 1; Fig. 2). This raises an important question: what are the functional distinctions between ASCs and committed preadipocytes in vivo? In Fig. 2, we present ASCs as a potentially self-renewing intermediate between pericytic SVCs and committed preadipocytes, implying that ASCs might contribute to preadipocyte formation and, thereby, WAT expansion. But are ASCs really required to replenish the population of committed preadipocytes? As mentioned above, the observations of Graff and colleagues suggest that most preadipocyte commitment occurs prenatally or just after birth, and that committed preadipocytes self-renew to replenish those lost during adipogenesis (24) (Fig. 2). These observations suggest that preadipocytes do not derive from ASCs postnatally, which brings into question the role of ASCs in the context of WAT biology. More importantly, this line of reasoning relies on the assumption that ASCs are a genuine, functionally distinct cell type; without definitive proof that, in vivo, ASCs are genuine stem cells, it remains possible that ASCs and committed preadipocytes are essentially the same cell, with multipotency and other distinctions only apparent in experimental contexts. This brings into question not only the purpose of ASCs, but also their very existence.

PERSPECTIVES AND CONCLUSIONS

The past century has witnessed huge strides in our understanding of stem cell biology, WAT expansion, and preadipocyte differentiation, which laid the foundation for the identification of adipose tissue-derived stem cells at the turn of the millennium. Research over the past decade has since established the utility of ASCs for tissue engineering and regenerative medicine, which may shift our perceptions: rather than being a cause of ill health, adipose tissue might also harbor potential cures. Despite this promise, much remains to be known about ASCs from a more physiological perspective. Are ASCs truly self-renewing, multipotent stem cells? Are they even a discrete cell type at all? While these important questions have yet to be answered, ASC research has contributed to more-recent progress in the characterization of committed preadipocytes. Viewed in this context, our knowledge of the ASC provides valuable insights into the mechanisms underlying preadipocyte commitment. Exploration of ASCs has thereby fed back into research at the root of their discovery, echoing the words of T.S. Elliot:

We shall not cease from exploration, and the end of all our exploring will be to arrive where we started and know the place for the first time.

But because our exploration has not yet ended, knowledge of both ASC biology and preadipocyte commitment will surely continue expanding in the future.

REFERENCES

1. Fleck, S. J. 1983. Body composition of elite American athletes. Am. J. Sports Med. 11: 398–403.
2. Ortega, F. J., D. Mayas, J. M. Moreno-Navarrete, V. Catalan, J. Gomez-Ambrosi, E. Esteve, J. I. Rodriguez-Hermosa, B. Ruiz, W. Ricart, B. Peral, et al. 2010. The gene expression of the main lipogenic enzymes is downregulated in visceral adipose tissue of obese subjects. Obesity (Silver Spring). 18: 13–20.
3. Larson, K. A., and D. B. Anderson. 1978. The effects of lipectomy on remaining adipose tissue depots in the Sprague Dawley rat. Growth. 42: 469–477.
4. Reyne, Y., J. Nougues, and A. Vezinhet. 1983. Adipose tissue regeneration in 6-month-old and adult rabbits following lipectomy. Proc. Soc. Exp. Biol. Med. 174: 258–264.
53. Farmer, S. R. 2006. Transcriptional control of adipocyte formation. Cell Metab. 4: 263–273.
54. Rosen, D. E., and O. A. MacDougall. 2006. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7: 885–896.
55. Christodoulides, C., C. Lagathu, J. K. Sethi, and A. Vidal-Puig. 2009. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 20: 16–24.
56. Lefterova, M. I., and M. A. Lazar. 2009. New developments in adipogenesis. Trends Endocrinol. Metab. 20: 107–114.
57. Lowe, C. E., S. O’Rahilly, and J. J. Rochford. 2011. Adipogenesis at a glance. J. Cell Sci. 124: 2081–2086.
58. Eguchi, J., Q. W. Yan, D. E. Schones, M. Kanal, C. H. Hsu, M. Q. Zhang, G. E. Crawford, and E. D. Rosen. 2008. Interferon regulatory factors are transcriptional regulators of adipogenesis. Cell Metab. 7: 86–94.
59. Nielsen, R., T. A. Pedersen, D. Hagenbeek, P. Moulos, R. Siersbaek, D. Steger, G. R. Grant, M. Schupp, T. Tomaru, M. I. Lefterova, J. Till, J. E. Till, and E. A. McCulloch. 2011. A stochastic model of stem cell proliferation through an epigenomic transition state. Genes Dev. 25: 2953–2967.
60. Amsel, S., and E. S. Dell. 1972. Bone formation by hemopoietic tissues. Science 176: 71–74.
61. Friedenstein, A. J., R. K. Chalakhyan, and U. V. Gerasimov. 1987. Bone marrow osteogenic stem cells: in vitro cultivation and transdifferentiation in differentiation chambers. Cell Tissue Kinet. 20: 263–272.
62. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshall. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143–147.
63. Pereira, R. F., K. W. Halford, M. D. O’Hara, D. B. Leeper, B. P. Skokos, M. Pollard, O. Bagasta, and A. J. Prokop. 1995. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc. Natl. Acad. Sci. USA 92: 4857–4861.
64. Krebsbach, P. H., S. A. Kuznetsov, K. Satomura, R. V. Emmons, D. W. Rowe, and P. G. Robey. 1997. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J. Bone Miner. Res. 12: 1335–1347.
65. Morrison, S. J., N. M. Shah, and D. J. Anderson. 1999. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 96: 737–749.
66. da Silva Meirelles, L., P. C. Chagastelles, and N. B. Nardi. 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119: 2204–2213.
67. Halvorsen, Y. C., W. O. Wilkison, and J. M. Gimble. 2000. Adipose-derived stromal cells—their utility and potential in bone formation. Int. J. Obses. Relat. Metab. Disord. 24 (Suppl. 1): 41–44.
68. Zuk, P. A., M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J. Katz, P. Benhaim, H. P. Lorenz, and M. H. Hedrick. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7: 211–223.
69. Halvorsen, Y. D., D. Franklin, A. L. Bond, D. C. Hitt, C. Aucber, A. L. Boskey, E. P. Paschalis, W. O. Wilkison, and J. M. Gimble. 2001. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. Tissue Eng. 7: 729–741.
70. Gimble, J. M., A. J. Katz, and B. A. Bunnell. 2007. Adipose-derived stem cells for regenerative medicine. Circ. Res. 100: 1249–1260.
71. Zhang, M. H., Z. C. Alfonso, J. K. Fraser, P. Benhaim, and M. H. Hedrick. 2002. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell. 13: 4279–4295.
72. De Ugarte, D. A., K. Morizono, A. Elbarbary, Z. Alfonso, P. A. Zuk, M. Zhu, J. L. Dragoo, P. Ashjian, B. Thomas, P. Benhaim, et al. 2003. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174: 101–109.
73. Drago, J. L., J. Y. Choi, J. R. Lieberman, J. Huang, P. A. Zuk, J. Zhang, M. H. Hedrick, and P. Benhaim. 2003. Bone induction by BMP-2 transduced stem cells derived from human fat. J. Orthop. Res. 21: 622–629.
74. Ashjian, P. H., A. S. Elbarbary, B. Edmonds, D. De Ugarte, M. Zhu, P. A. Zuk, H. P. Lorenz, P. Benhaim, and M. H. Hedrick. 2003. In vitro differentiation of human processed liposapirellate cells into early neural progenitors. Plast. Reconstr. Surg. 111: 1922–1931.
75. Lin, E., X. Chen, L. Liu, J. Qiao, Z. Yao, Z. Li, W. Tang, X. Zheng, and W. Tian. 2005. Molecular and cellular characterization during chondrogenic differentiation of adipose tissue-derived stromal cells in vitro and cartilage formation in vivo. J. Cell. Mol. Med. 9: 929–939.
76. Grouthos, S. M., D. M. Franklin, H. A. Leddy, P. G. Robey, R. W. Storms, and J. M. Gimble. 2001. Surface protein characterization of human adipose tissue-derived stromal cells. J. Cell. Physiol. 189: 54–63.
77. Lee, M. J., S. Y. Suh, Y. C. Bae, and J. S. Jung. 2005. Differentiation of human adipose tissue cells into hepatic lineage in vitro and in vivo. Biochem. Biophys. Res. Commun. 328: 258–264.
78. Ning, H., G. Lin, T. F. Lue, and C. S. Lin. 2006. Neuron-like differentiation of adipose tissue-derived stromal cells and vascular smooth muscle cells. Differentiation 74: 510–518.
79. Hwa Cho, H., Y. C. Bae, and J. S. Jung. 2006. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24: 2744–2752.
80. Song, A., S. Breit, D. Parsh, K. Benz, E. Steck, H. Hauner, R. M. Weber, V. Ewerbeck, and W. Richter. 2009. Cartilage-like gene expression in differentiated human stem cell spheroids: a comparison of bone marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum. 48: 418–429.
81. Wang, J., P. A. Zuk, M. H. Hedrick, and P. Benhaim. 2003. Improvement of neuronal deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. Exp. Neurol. 183: 355–366.
82. Lee, R. H., B. Kim, I. Choi, H. Kim, H. S. Choi, K. Suh, Y. C. Bae, and J. S. Jung. 2005. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell. Physiol. Biochem. 14: 311–324.
83. Song, A. M., Y. Y. Shi, O. O. Aalami, Y. F. Chou, C. Mari, R. Thomas, N. Quarto, C. H. Contag, B. Wu, and M. T. Longaker. 2004. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat. Biotechnol. 22: 560–567.
84. Safford, K. M., S. D. Safford, J. M. Gimble, A. K. Shetty, and H. E. Rice. 2004. Characterization of neuronal/glia differentiation of murine adipose-derived adult stromal cells. Exp. Neurol. 187: 319–328.
85. Safford, K. M., K. C. Hick, S. D. Safford, Y. D. Halvorsen, W. O. Wilkison, J. M. Gimble, and H. E. Rice. 2002. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem. Biophys. Res. Commun. 294: 371–379.
86. Aust, L., B. Devlin, S. J. Foster, Y. D. Halvorsen, K. Hick, T. du Laney, A. Sen, G. D. Willingmyre, and J. M. Gimble. 2004. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 6: 7–14.
Adipose tissue stem cells meet preadipocyte commitment

97. Miranville, A., C. Heeschen, C. Sengenes, C. A. Curat, R. Busse, and A. Bouloumie. 2004. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 110: 349–355.

98. Nakagami, H., K. Maeda, R. Morishita, S. Iguchi, T. Nishikawa, Y. Takami, Y. Kikuchi, Y. Saito, K. Tanaka, T. Oghara, et al. 2005. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler. Thromb. Vasc. Biol. 25: 2452–2457.

99. Toyoda, M., Y. Matsubara, K. Lin, K. Sugimachi, and M. Furue. 2010. Characterization and comparison of adipose tissue-derived cells from human subcutaneous and omental adipose tissues. Cell Transplant. 19: 447–457.

100. Kang, Y., C. Park, D. Kim, C. M. Seong, K. Kwon, and C. Choi. 2010. Untorted human adipose tissue-derived stem cells promote angiogenesis and myogenesis in murine ischemic hindlimb model. Microvasc. Res. 80: 310–316.

101. Kajiyama, H., T. S. Hamazaki, M. Tokuhara, S. Masui, K. Okahayashi, K. Ohnuma, S. Yabe, Y. Yasuda, S. Ishiiura, H. Okochi, et al. 2010. Pdxt1-transduced adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. Int. J. Dev. Biol. 54: 699–705.

102. Levi, B., A. W. James, E. R. Nelson, D. Vistnes, B. Wu, M. Lee, A. Gupta, and M. T. Longaker. 2010. Human adipose derived stromal cells heal critical size mouse calvarial defects. PLoS ONE. 5: e11177.

103. Mitchell, J. B., K. McIntosh, S. Zvonic, S. Garrett, Z. E. Floyd, A. Katz, A. Tholpady, S. S. Tholpady, H. Shang, and R. C. Ogle. 2006. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler. Thromb. Vasc. Biol. 25: 2452–2457.

104. Di Rocco, G., M. G. Iachininoto, A. Tritarelli, S. Straino, A. Zacheo, Y. Matsubara, K. Lin, K. Sugimachi, and M. Furue. 2010. Histochem. Cell Biol. 134: 569–578.

105. McVey, A. J., F. J. R. Rehn, N. Sousa, and J. M. Gimble. 2010. Adipose tissue derived stem cells secrete soluble factors and their roles in regenerative medicine. Curr. Stem Cell Res. Ther. 5: 103–110.

106. Biomaterials. 2004. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 109: 656–663.

107. Scheideler, M., C. Elabd, L. E. Zaragosi, C. Chiellini, H. Hackl, F. Sanchez-Cabo, S. Yadav, K. Dusza, G. Friedl, C. Papak, et al. 2008. Comparative transcriptomics of human multipotent stem cells during adipogenesis and osteoblastogenesis. BMC Genomics. 9: 340.

108. Quirici, N., C. Scavullo, L. De Girolamo, S. Lopa, E. Arrigoni, G. L. Bruni, et al. 2010. Anti-L-NGFR and -CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. Stem Cells Dev. 19: 915–925.

109. Conget, P. A., and J. M. Minguell. 1999. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J. Cell. Physiol. 181: 67–73.

110. Zheng, B., B. Cao, G. Li, and J. Huard. 2006. Mouse adipose-derived stem cells undergo multilineage differentiation in vitro but primarily originate and chondrogenic differentiation in vivo. Tissue Eng. 12: 1891–1901.

111. Crisan, M., S. Yap, L. Castella, C. W. Chen, M. Corselli, T. S. Park, G. Andriolo, B. Sun, B. Zheng, L. Zhang, et al. 2008. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 3: 301–313.

112. RHODIN, J. A. 1968. Ultrastructure of mammalian venous capillaries, venules, and small collecting veins. J. Ultrastruct. Res. 25: 450–560.

113. Sugita, H., D. Matsumoto, H. Eto, K. Inoue, N. Aoi, H. Kato, J. Araki, and K. Yoshimura. 2009. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev. 18: 1291–1210.

114. Li, H., L. Zimmerlin, K. G. Marra, V. S. Donnenberg, A. D. Donnenberg, and J. P. Rubin. 2011. Adipogenic potential of adipose stem cell subpopulations. Plast. Reconstr. Surg. 128: 663–672.

115. Planat-Bénard, V., C. Menard, M. Andre, M. Puceat, A. Perez, J. M. Garcia-Verdugo, L. Penicaud, and L. Castella. 2004. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res. 94: 223–229.

116. Rodriguez, L. V., Z. Alfonso, R. Zhang, J. Leung, B. Wu, and L. J. Ignarro. 2006. Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. Proc. Natl. Acad. Sci. USA. 103: 12167–12172.

117. Xu, Y., L. Liu, Y. Li, C. Zhou, F. Xiong, Z. Liu, R. Gu, X. Hou, and C. Zhang. 2008. Myelin-forming ability of Schwann cell-like cells induced from rat adipose-derived stem cells in vitro. Brain Res. 1239: 49–55.

118. Lee, J. A., B. M. Parrett, J. A. Conejero, J. Laser, J. Chen, A. J. Kogon, D. Nanda, R. T. Grant, and A. S. Breitbart. 2003. Biological alchemy: engineering bone and fat from fat-derived stem cells. Ann. Plast. Surg. 50: 61–69.

119. Choi, Y. S., S. M. Cha, Y. Y. Lee, S. W. Kwon, C. J. Park, and M. Kim. 2006. Adipogenic differentiation of adipose tissue derived adult stem cells in nude mouse. Biochem. Biophys. Res. Commun. 345: 631–637.

120. Mauney, J. R., T. Nguyen, K. Gillen, C. Kirker-Head, J. M. Gimble, and D. L. Kaplan. 2007. Engineering adipose-tissue-like tissue in vivo and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds. Biomaterials. 28: 5290–5299.

121. Fischbach, C., T. Spruss, B. Weiser, M. Neubauer, C. Becker, M. Hacker, A. Gopferich, and T. Blunk. 2004. Generation of mature fat pads in vitro and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds. Biomaterials. 25: 807–815.

122. Chei, Y. S., S. N. Park, and H. Suh. 2005. Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres. Biomaterials. 26: 5855–5863.

123. Neubauer, M., M. Hacker, P. Bauer-Kreisel, B. Weiser, C. Fischbach, M. B. Schulz, A. Gopferich, and T. Blunk. 2005. Adipose tissue engineering based on mesenchymal stem cells and basic fibroblast growth factor in vitro. Tissue Eng. 11: 1840–1851.

124. Schetz, T. J., T. L. Huang, T. T. Tran, H. Zhang, K. L. Townsend, J. L. Shadrach, M. Cerletti, L. E. McDougall, N. Giorgadze, T.

125. Biochem. Exp. Cell Res. 200: 315–317.

126. Tissue Eng. 11: 1840–1851.
et al. 2009. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 58: 570–581.

176. Kim, D. H., C. M. Je, J. Y. Sin, and J. S. Jung. 2003. Effect of partial hepatectomy on in vivo engraftment after intravenous administration of human adipose tissue stromal cells in mouse. Microsurgery. 23: 423–431.

177. Banas, A., T. Teratani, Y. Yamamoto, M. Tokuhara, F. Takeshita, M. Osaki, T. Kato, H. Okochi, and T. Ochiya. 2009. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J. Gastroenterol. Hepatol. 24: 70–77.

178. Wang, X., H. Willenbring, Y. Akkari, Y. Torimaru, M. Foster, M. A. Hilal, E. Lagasse, M. Finegold, S. Olson, and M. Gromeo. 2003. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 422: 897–901.

179. Vassilopoulos, G., P. R. Wang, and D. W. Russell. 2003. Transplanted bone marrow regenerates liver by cell fusion. Nature. 422: 901–904.

180. Timper, K., D. Schoek, M. Eberhardt, P. Linscheid, P. Christ-Vassilopoulos, G., P. R. Wang, and D. W. Russell. 2003. Transplanted bone marrow regenerates liver by cell fusion. Nature. 422: 901–904.

181. Zingaretti, M. C., F. Crosta, A. Vitali, M. Guerrieri, A. Frontini, B.annon, J. Nedergraaf, and S. Cinti. 2009. The presence of UCPI demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 23: 3113–3120.

182. Gupta, R. K., Z. Arany, P. Seale, R. M. Jepson, L. Y. Li, H. M. Conroe, Y. A. Roby, H. Kulgara, R. R. Reed, and B. M. Spiegelman. 2010. Transcriptional control of preadipocyte differentiation by Zfip423. Nature. 464: 619–623.

183. Quach, J. M., E. C. Walker, E. Allan, M. Solano, A. Yokoyama, S. Kato, N. A. Sims, M. T. Gillespie, and T. J. Martin. 2011. Zinc finger protein 167 is a novel regulator of osteoblast and adipocyte differentiation. J. Biol. Chem. 286: 4186–4198.

184. Rajashekar, G., D. O. Traktuev, W. C. Roell, B. H. Johnstone, S. Merfeld-Clauss, B. Van Natta, E. D. Rosen, K. L. March, and M. C. Cash. 2008. IFATs collection: adipose stromal cell differentiation is reduced by endothelial cell contact and paracrine communication: role of canonical Wnt signaling. Stem Cells. 26: 2067–2081.

185. Ross, S. E., N. Hemati, K. A. Longo, C. N. Bennett, P. C. Lucas, R. L. Erickson, and O. A. MacDougall. 2000. Inhibition of adipogenesis by Wnt signaling. Science. 289: 950–953.

186. Longo, K. A., W. S. Wright, S. Kang, I. Gerin, S. H. Chiang, P. C. Lucas, M. R. Opp, and O. A. MacDougall. 2004. Wnt10b inhibits development of white and brown adipose tissues. J. Biol. Chem. 279: 55503–55509.

187. Kang, S., L. Bajnok, K. A. Longo, R. K. Petersen, J. B. Hansen, K. Kristiansen, and O. A. MacDougall. 2005. Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol. Cell. Biol. 25: 1272–1282.

188. Wright, W. S., K. A. Longo, W. V. Dolinsky, I. Gerin, S. Kang, C. N. Bennett, S. H. Chiang, T. C. Prestwich, C. Gress, C. F. Burant, et al. 2007. Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes. 56: 295–303.

189. Cawthorn, W. P., A. J. Bree, Y. Yao, B. Du, N. Hemati, G. Martinez-Saninez, and O. A. MacDougall. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone Eubp ahead of print. August 18, 2011; doi: 10.1016/j.bone.2011.08.010.

190. Bondyadi, M., S. D. Waldman, D. Liu, J. E. Aubin, M. D. Gynpaa, and W. L. Stanford. 2003. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca1-1/Ly-6a null mice. Proc. Natl. Acad. Sci. USA. 100: 5840–5845.

191. Torri, F. M., S. V. Torri, J. W. Larrick, and G. M. Ringold. 1989. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor beta. J. Cell Biol. 108: 1105–1113.

192. Choy, L., and R. Deynck. 2003. Transforming growth factor-beta inhibits adipocyte differentiation by Smaod3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J. Biol. Chem. 278: 9699–9619.

193. Chow, L., J. Skillington, and R. Deynck. 2000. Roles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiation. J. Cell Biol. 149: 667–682.

194. Artemenko, Y., A. Gagnon, D. Aubin, and A. Sorisky. 2005. Anti-adipogenic effect of PDGF is reversed by PKC inhibition. J. Cell. Physiol. 204: 646–653.

195. Dührs, U., T. Martinez, G. Vohnwinkel, S. Ergun, L. Sun, G. McMahon, J. Durig, D. K. Hosfeld, and W. Fiedler. 2001. Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow. Growth Factors. 19: 1–17.

196. Camp, H. S., and S. R. Tafuri. 1997. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem. 272: 10831–10836.

197. Krieger-Brauer, H. I., and H. Kather. 1995. Antagonistic effects of different members of the fibroblast and platelet-derived growth factor families on adipose conversion and NADPH-dependent H2O2 generation in 3T3 L1-cells. Biochem. J. 307: 549–556.

198. Takashima, Y., T. Era, K. Nakao, S. Kondo, M. Kasuga, A. G. Smith, and S. Nishikawa. 2007. Neural progenitor cells supply an initial transient wave of MSC differentiation. Cell. 129: 1377–1388.

199. Umezui, A., S. Fukada, Y. Yamamoto, S. Takeda, and K. Tsuichida. 2010. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat. Cell Biol. 12: 145–152.

200. Festa, E., J. Fretz, R. Berry, B. Schmidt, M. Rodeheffer, M. Horowitz, and V. Horsley. 2011. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. Cell. 146: 761–771.

Adipose tissue stem cells meet preadipocyte commitment 245
215. Taylor, S. M., and P. A. Jones. 1979. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell: 17: 771–779.

216. Katagiri, T., A. Yamauchi, T. Ikeda, S. Yoshih, J. M. Wozney, V. Rosen, E. A. Wang, H. Tanaka, S. Osumi, and T. Suda. 1990. The mouse osteoblast cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem. Biophys. Res. Commun. 172: 295–299.

217. Tseng, Y.H., E. Kokotou, T. J. Schulz, T. L. Huang, J. N. Winnay, C. Majka, S. E. Fox, J. C. Psilas, K. M. Helm, C. R. Childs, A. S. Crossno, J. T., Jr., S. M. Majka, T. Grazia, R. G. Gill, and D. J. Taylor, S. M., and P. A. Jones. 1979. Multiple new phenotypes in-...